摘要:
Improved strategies for a Cyclical Redundancy Check (CRC) are disclosed. A CRC check of a codeblock may be initiated by a CRC decoder before receiving all of the bits by a corresponding FEC encoder. Furthermore, an incremental CRC check with respect to the data packet without the need for requesting passed through data from higher layers.
摘要:
The disclosure relates generally to the field of communications in transceiver, and more particularly to improved strategies for Cyclical Redundancy Check (CRC). A CRC check of a codeblock may be initiated by a CRC decoder before receiving all of the bits by a corresponding FEC encoder. Furthermore, an incremental CRC check with respect to the data packet without the need for requesting passed through data from higher layers.
摘要:
A wireless communication device is disclosed that is capable of reduced power consumption. Uplink and downlink sub-frames in a WiMAX, 802.16m or LTE environment often include several vacant symbols during which power-hungry hardware and software components need not operate at full power. By analyzing a physical layer beacon and control information of a received signal, the specific locations of data bursts can be determined, as well as periods of needed operation of a receiver module to effectively decode those data bursts. The receiver module can otherwise be controlled to operate in a LOW power state during remaining periods of vacant time, thereby conserving power consumption and extending battery life.
摘要:
A wireless communication device is disclosed that is capable of reduced power consumption. Uplink and downlink sub-frames in a WiMAX, 802.16m or LTE environment often include several vacant symbols during which power-hungry hardware and software components need not operate at full power. By analyzing a physical layer beacon and control information of a received signal, the specific locations of data bursts can be determined, as well as periods of needed operation of a receiver module to effectively decode those data bursts. The receiver module can otherwise be controlled to operate in a LOW power state during remaining periods of vacant time, thereby conserving power consumption and extending battery life.
摘要:
Methods and apparatus of allocating antennas for cyclic delay diversity (CDD) transmission are disclosed. One method includes estimating a transmission channel of a transceiver having a plurality of antennas. A subset of a plurality of transceiver antennas is selected based on the estimated transmission channel. A single transceiver antenna of the subset is identified based on a channel quality of a transmission path of the single transceiver antenna. Cyclic delay diversity (CDD) signals are transmitted from the subset of the plurality of antennas, wherein a minimally delayed CDD signal is transmitted from the identified single transceiver antenna of the subset of the plurality of transceiver antennas.
摘要:
Provided herein are novel bridged cyclic derivatives of the general formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds can inhibit HDACs and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, neurode-generative disorders etc.
摘要:
Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I).
摘要:
The present invention relates to novel heterocyclic compounds of the general formula (I), as IL-6 inhibitors, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly provides novel heterocyclic compounds of the general formula (I). Also included is a method for treatment of cancer, cancer cachexia and inflammatory diseases including immunological diseases, particularly those mediated by cytokines such as IL-6, through pSTAT3 inhibition, in a mammal comprising administering an effective amount of a compound of formula (I) as described above.
摘要:
The present invention relates to novel anticancer agents, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The present invention more particularly relates to novel derivatives of andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of andrographolide have the general formula (I).